

NEWS RELEASE

NeuroVive Pharmaceutical AB (publ)
556595-6538

29 January 2014



NeuroVive extends partnership agreement with InVentiv Health to prepare for upcoming market launch

Agreement expands consulting services acquired by NeuroVive, with the possibility of a broader partnership for development and commercialization services

NeuroVive Pharmaceutical AB (publ), a leading mitochondrial medicine company specializing in drugs that treat acute cardiovascular and neurological conditions, extends the partnership agreement with inVentiv Health, an important strategic partner that offers best-in-class clinical, commercial and consulting services.

NeuroVive, with a promising portfolio of mitochondrial drugs in development to treat acute cardiovascular and neurological conditions, has been evaluating various collaborations with large pharmaceutical companies and contract research organizations to reduce risk and increase cost efficiencies. The company is currently in the planning stage for commercialization of its lead product, CicloMulsion®, now in a Phase III study to determine the drug's effectiveness in reducing cardiac damage following stenting in heart attack patients.

inVentiv Health works with pharmaceutical and biotechnology firms to help define innovative alternatives to traditional development and commercialization models. inVentiv offers mid-size pharmaceutical and biopharmaceutical companies an expansive set of services that run from early-stage clinical development to full global commercialization. The breadth of inVentiv Health's services is unique in the industry and includes comprehensive drug development, risk management, market access and reimbursement, launch, marketing communications, payer relations and patient outcomes.

NeuroVive is looking for a partner with an alternative business model that can commercialize CicloMulsion® and be leveraged to scale for future products. By working with inVentiv, the company will be able to maintain more control and value while moving faster to market.

"We are very pleased to extend the collaboration with inVentiv Health, an important step in preparing the market for launch of CicloMulsion® in Europe and, later, in the United States," said Mikael Brönnegård, CEO of NeuroVive Pharmaceutical AB. "inVentiv Health's commercial services will provide a valuable platform for optimal market penetration at later stages and when approaching the launch and marketing of the product."

NeuroVive recently completed a one-year regulatory consulting project with ParagonRx, inVentiv's risk mitigation service. inVentiv will next be providing market assessment services through its consulting arm, Campbell Alliance. Campbell, a leading health care consulting firm, helps companies sell more effectively in an environment increasingly dominated by third-party payers. The work will start immediately with an assessment of the US market and a continuation of the prelaunch activities and a plan for the market introduction in Europe.

NEWS RELEASE

NeuroVive Pharmaceutical AB (publ)
556595-6538



29 January 2014

NeuroVive and inVentiv also are discussing a broader expansion of the partnership to include future development and commercialization services for CicloMulsion®.

“We’re big enough to step in and provide NeuroVive with virtually any service they require to develop and commercialize their compound, and we’re flexible enough to align with whatever they need to achieve their objectives,” said Dan Feldman, President of inVentiv Health Europe.

“Pharmaceutical companies face a far more challenging market environment than ever before. Today’s market requires innovative strategic partnerships. inVentiv Health was created to provide this new model for the new marketplace.”

About NeuroVive

NeuroVive Pharmaceutical AB (publ), a leading mitochondrial medicine company, is developing a portfolio of products to treat acute cardiovascular and neurological conditions through mitochondrial protection. These medical conditions are characterized by a pressing medical need and have no approved pharmaceutical treatment options at present. NeuroVive’s products CicloMulsion® (heart attack) and NeuroSTAT® (traumatic brain injury) are currently being evaluated in phase III and phase II studies, respectively. NeuroVive’s research programs also include products for the treatment of anti-viral indications (Hepatitis B/C), brain cell injury in stroke patients, and drug candidates for cellular protection and treating mitochondria-related energy regulation diseases. NeuroVive’s shares are listed on NASDAQ OMX, Stockholm, Sweden.

About inVentiv Health

InVentiv Health’s broad range of services and global scale, represented by approximately 12,000 employees supporting clients in more than 70 countries, allow the firm to serve as a critical strategic partner for pharmaceutical, biotechnology, medical device and diagnostics, and healthcare companies in their dynamic and rapidly changing regulatory and commercial environments. InVentiv Health serves more than 550 client organizations, including all 20 of the largest global pharmaceutical companies. For more information, visit www.inVentivHealth.com.

Media and investor relations questions to:

Ingmar Rentzhog, Laika Consulting, Tel: +46 (0)46 275 6221 or ir@neurovive.se

Please also use the above contact if you wish to arrange an interview with NeuroVive’s CEO, Mikael Brönnegård.

NeuroVive Pharmaceutical AB (publ)

Medicon Village, SE-223 81 Lund, Sweden, Tel: +46 (0)46 275 6220 (switchboard), Fax: +46 (0)46 888 8348
info@neurovive.se, www.neurovive.se

inVentiv Health, Inc.

Danielle DeForge, Director, Corporate Communications, +1 781 425 4624,
Danielle.DeForge@inVentivhealth.com



NeuroVive Pharmaceutical AB (publ) is obligated to publish the information contained in this news release in accordance with the Swedish Securities Market Act. This information was provided to the media for publication at 13:00 CEST on 29 January 2014.

NeuroVive Pharmaceutical AB (publ) is a leading mitochondrial medicine company. The company is listed on NASDAQ OMX Stockholm, Small Cap, with the stock symbol NVP. IR-related questions should be addressed to ir@neurovive.com or +46(0)46 275 6221.